About The Study

Ulcerative Colitis is a chronic inflammatory bowel disease characterized by inflammation and ulcers in the colon and rectum lining. This condition typically manifests with symptoms such as abdominal pain, diarrhea, and rectal bleeding. The exact cause of ulcerative colitis remains unknown, but it is believed to involve a combination of genetic, environmental, and immune system factors. The severity of symptoms can vary, with periods of remission and flare-ups. Management often involves medications to control inflammation, lifestyle adjustments, and in some cases, surgery.  

 The purpose of this study at RCR is to evaluate the safety and effectiveness of an investigational oral medication taken at 2 different doses vs placebo on clinical remission of ulcerative colitis. This is a phase 3 study, and the investigational product has shown promising results when treating Ulcerative Colitis in previous phases.   


  • Must be 18 years or older
  • Must have a documented diagnosis of Ulcerative Colitis from a prior endoscopy
  • Must have symptoms of active disease (such as increased stool frequency from baseline and blood in stools)
  • *Please note, other qualifications apply